• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $VERA

    Vera Therapeutics Inc.

    Subscribe to $VERA
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: veratx.com

    Recent Analyst Ratings for Vera Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    5/5/2025$75.00Buy
    H.C. Wainwright
    2/4/2025$49.00Outperform
    Wolfe Research
    1/28/2025$58.00Buy
    Goldman
    11/21/2024$70.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    1/25/2024$26.00Outperform
    Oppenheimer
    1/8/2024Overweight
    Cantor Fitzgerald
    12/18/2023$29.00Outperform
    Raymond James
    11/10/2023$18.00 → $26.00Hold → Buy
    Jefferies
    8/16/2023$27.00Buy
    Guggenheim
    See more ratings

    Vera Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Enright Patrick G bought $5,277,311 worth of shares (250,000 units at $21.11) (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      6/25/25 8:07:16 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Katabi Maha bought $4,999,990 worth of shares (161,290 units at $31.00) (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      2/1/24 5:58:54 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Vera Therapeutics Inc. SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Vera Therapeutics Inc.

      SCHEDULE 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

      6/11/25 5:38:07 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

      6/3/25 6:36:50 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

      6/2/25 6:36:56 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

      5/19/25 4:41:17 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

      5/6/25 8:00:11 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Vera Therapeutics Inc.

      DEFA14A - Vera Therapeutics, Inc. (0001831828) (Filer)

      4/3/25 4:08:41 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Vera Therapeutics Inc.

      DEF 14A - Vera Therapeutics, Inc. (0001831828) (Filer)

      4/3/25 4:06:57 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Vera Therapeutics Inc.

      S-8 - Vera Therapeutics, Inc. (0001831828) (Filer)

      2/28/25 4:44:11 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Vera Therapeutics Inc.

      10-K - Vera Therapeutics, Inc. (0001831828) (Filer)

      2/28/25 4:00:33 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

      2/26/25 8:00:10 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Vera Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Vera Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Vera Therapeutics with a rating of Buy and set a new price target of $75.00

      5/5/25 9:37:24 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Vera Therapeutics with a new price target

      Wolfe Research initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $49.00

      2/4/25 7:12:11 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Vera Therapeutics with a new price target

      Goldman initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $58.00

      1/28/25 8:54:12 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Vera Therapeutics with a new price target

      Wells Fargo initiated coverage of Vera Therapeutics with a rating of Overweight and set a new price target of $70.00

      11/21/24 7:48:14 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Vera Therapeutics

      Scotiabank initiated coverage of Vera Therapeutics with a rating of Sector Outperform

      10/16/24 8:39:33 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Vera Therapeutics with a new price target

      Oppenheimer initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $26.00

      1/25/24 7:40:48 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Vera Therapeutics

      Cantor Fitzgerald initiated coverage of Vera Therapeutics with a rating of Overweight

      1/8/24 8:23:42 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on Vera Therapeutics with a new price target

      Raymond James initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $29.00

      12/18/23 8:10:14 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics upgraded by Jefferies with a new price target

      Jefferies upgraded Vera Therapeutics from Hold to Buy and set a new price target of $26.00 from $18.00 previously

      11/10/23 7:22:48 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Vera Therapeutics with a new price target

      Guggenheim initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $27.00

      8/16/23 7:27:11 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Vera Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common stock to fifteen (15) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on July 6, 2025 has an exercise price per share equal to $24.00, Vera's closing trading price on July 3, 2

      7/10/25 7:05:19 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on June 3, 2025 has an exercise price per share equal to $30.91, Vera's closing trading price on June 3,

      6/9/25 4:05:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

      BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami Beach, FL from June 9 – 11, 2025. The management team will also participate in one-on-one investor meetings. Fireside Chat Details:Date: Wednesday, June 11, 2025 Time: 3:15pm EDTWebcast: https://cc.webcasts.com/gold006/060925a_js/?entity=165_UH4O74B A replay of

      6/4/25 4:05:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

      BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. ("Vera"), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has entered into a new credit facility providing for up to $500 million of term loans with its current partner Oxford Finance LLC ("Oxford"). The new credit facility will replace Vera's existing $50 million credit facility. The initial funding of the new credit facility will be in a principal amount of $75 million and is expected to occur on June 4, 2025. Highlights of the new credit facility include: Lowered Interest Ra

      6/3/25 6:30:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

      Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continuesThe safety profile of atacicept was favorable, and comparable to placebo Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application

      6/2/25 6:30:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on May 5, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 111,750 shares of Class A common stock and restricted stock units (RSUs) for 62,575 shares of Class A common stock to eleven (11) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on May 5, 2025 has an exercise price per share equal to $25.53, Vera's closing trading price on May 5, 2025. E

      5/9/25 4:05:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

      On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for Biologics License Application (BLA) submission for atacicept accelerated approval to the U.S. FDA in 4Q 2025Expanded atacicept development program across multiple autoimmune kidney diseases is underway BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March

      5/6/25 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 211,250 shares of Class A common stock and restricted stock units (RSUs) for 105,125 shares of Class A common stock to sixteen (16) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on April 3, 2025 has an exercise price per share equal to $22.74, Vera's closing trading price on April

      4/9/25 4:05:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

      On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN). "We are grateful for the IgAN community's strong interest in the clinical development of atacicept that helped drive us towards completing

      4/3/25 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 51,500 shares of Class A common stock and restricted stock units (RSUs) for 25,750 shares of Class A common stock to nine (9) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on March 6, 2025, has an exercise price per share equal to $29.30, Vera's closing trading price on March

      3/11/25 4:28:05 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Vera Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Enright Patrick G bought $5,277,311 worth of shares (250,000 units at $21.11) (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      6/25/25 8:07:16 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Katabi Maha

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      5/16/25 4:13:51 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Enright Patrick G

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      5/16/25 4:13:01 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Oliger Christy J.

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      5/16/25 4:12:06 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Morrissey Michael

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      5/16/25 4:11:14 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Seidenberg Beth C

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      5/16/25 4:10:20 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hall Kimball

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      5/16/25 4:08:37 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Morrison Scott W

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      5/16/25 4:06:33 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cheng Andrew

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      5/16/25 4:05:20 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Fordyce Marshall sold $546,914 worth of shares (19,688 units at $27.78), decreasing direct ownership by 9% to 204,665 units (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      2/27/25 4:05:29 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Vera Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

      Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continuesThe safety profile of atacicept was favorable, and comparable to placebo Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application

      6/2/25 6:30:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

      BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. "This novel approach is part of Vera's broad lifecycle management strategy to expand and extend our leadership position within B cell modulation, which we believe has the potential to transform how we tre

      1/13/25 7:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

      New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population Atacicept was well tolerated with safety profile similar to placebo Positive results support atacicept 150 mg as a potential disease-modifying treatment for patients with IgA nephropathy; Phase 3 (ORIGIN 3) clinical trial initiated in June 2023 Conference call and webcast to take place on June 20th, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., June 17, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a la

      6/17/23 10:10:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

      Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current resources on the advancement of atacicept in IgA Nephropathy into a pivotal Phase 3 trial, extending cash runway to Q4 2024 Conference call and webcast to take place on January 30th at 8:00am ET BRISBANE, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced results from a prespecified per-protocol (PP)

      1/30/23 6:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

      Atacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data showing trend towards further reductions in proteinuria at week 36 Atacicept safety profile in IgAN patients was similar to placebo Vera plans to advance atacicept into a pivotal Phase 3 trial in the first half of 2023 Company to host investor conference call and webcast on January 4, 2023, at 8:00 a.m. ET to further discuss results  BRISBANE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing

      1/3/23 4:01:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics to Host Business Update Call

      BRISBANE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, will host a business update call at 8:00 a.m. ET on March 24, 2022. Title:Vera Therapeutics Business Update Call    Date:Thursday, March 24, 2022  Time:8:00 a.m. ET    Conference Call Details:Toll-Free: 1-877-423-9813International: 1-201-689-8573Conference ID: 13727899  Webcast:Webcast Link- Click Here The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusi

      3/17/22 7:30:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Vera Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

      SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 4:10:28 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

      SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 4:05:17 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Vera Therapeutics Inc.

      SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 1:22:39 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

      SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 12:15:08 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Vera Therapeutics Inc.

      SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 9:35:47 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

      SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/12/24 10:34:15 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vera Therapeutics Inc.

      SC 13D/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/4/24 7:49:25 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Vera Therapeutics Inc. (Amendment)

      SC 13D/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      3/26/24 7:57:53 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Vera Therapeutics Inc. (Amendment)

      SC 13D/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      2/20/24 7:11:22 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vera Therapeutics Inc. (Amendment)

      SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      2/14/24 4:57:08 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Vera Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

      BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. "We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us succ

      11/18/24 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

      BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. "We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. We expect long-term 96-week data from the Phase 2b ORIGIN trial later this year and primary endpoint results from our pivotal Phase 3 clinical trial in the first half of 2025, and we look forward to

      7/1/24 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

      BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches. "We are delighted to welcome Christy to our Board during this important period in Vera's history. Her extensive experience and counsel will be

      6/11/24 4:01:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

      BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the appointments of two industry veterans to help lead the development of the company's drug programs including its late-stage product candidate, atacicept, to treat autoimmune diseases, currently in a Phase 3 clinical trial for IgA nephropathy (IgAN). The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.; and William D. Turner as Chief Development Officer, effective immediately. "We

      1/8/24 8:01:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

      BRISBANE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced the appointment of Kerry Cooper, M.D., to the role of Senior Vice President, Medical Affairs, where he will report to Chief Medical Officer Celia Lin and be responsible for overseeing medical affairs strategy and scientific communications. Dr. Cooper brings nearly 40 years of experience in nephrology across a variety of senior positions within industry, clinical practice and academia. He has led medical affairs strategies for drug de

      5/4/23 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Innocoll Holdings Ltd. Appoints Kimball Hall as Chief Executive Officer

      Seasoned Commercial Operations Executive Positions Company for Next Stage of Growth Innocoll Holdings Ltd. ("IHL"), a global biotech pharmaceutical company and portfolio business of Gurnet Point Capital ("GPC"), today announced the appointment of Kimball Hall, a seasoned commercial operations executive, as President and Chief Executive Officer. As part of this appointment, Kimball will also serve as Chief Executive Officer of IHL's two subsidiaries: Syntacoll GmbH ("Syntacoll"), a contract development and manufacturing organization ("CDMO") specializing in collagen-based technology platforms, and Innocoll Biotherapeutics Inc. ("Innocoll"), a global biotech company focusing on delivering no

      1/26/23 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors

      BRISBANE, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, announced today the appointment Michael M. Morrissey, Ph.D., as chairman of its board of directors. Dr. Morrissey has served as president and chief executive officer (CEO) of Exelixis, Inc. since July 2010. "Mike's experience leading Exelixis' evolution into a fully integrated biopharmaceutical company will be immensely helpful to Vera as we prepare to move from late-stage clinical programs to potential commercial growth," said Kurt von Emster, Vera's cur

      4/12/22 7:30:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Appointment of Kimball Hall to Board of Directors

      BRISBANE, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Kimball Hall to its board of directors. Ms. Hall is a seasoned executive and a chemistry, manufacturing, and controls (CMC) expert. Formerly holding leadership positions at Genentech and Amgen, she is currently president and chief operating officer of Abzena, a biopharmaceutical focused contract development and manufacturing organization (CDMO). "We're honored to welcome Kimball to our board of directors," sai

      12/14/21 7:30:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Appoints Sean Grant as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Sean Grant, MBA as Chief Financial Officer. In this role, he will oversee all of Vera Therapeutics' financial operations including financial strategy, investor relations, accounting operations, financial planning and analysis, tax, and treasury. Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, commented, "We are fortunate to have an executive with Sean's financial acumen and pedigree join

      7/14/21 7:30:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care